{"id":"epidoxorubicine-docetaxel-cyclophosphamide","safety":{"commonSideEffects":[{"rate":"30-50%","effect":"Neutropenia"},{"rate":"20-40%","effect":"Anemia"},{"rate":"10-30%","effect":"Thrombocytopenia"},{"rate":"20-40%","effect":"Fatigue"},{"rate":"20-40%","effect":"Nausea"},{"rate":"10-30%","effect":"Vomiting"},{"rate":"10-30%","effect":"Diarrhea"},{"rate":"5-20%","effect":"Stomatitis"},{"rate":"50-70%","effect":"Hair loss"},{"rate":"10-30%","effect":"Infection"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Epidoxorubicine's mechanism of action is primarily through the inhibition of topoisomerase II, which is essential for DNA replication and cell division. Docetaxel's mechanism involves the stabilization of microtubules, preventing the separation of chromosomes during cell division. Cyclophosphamide's mechanism involves the alkylation of DNA, leading to DNA damage and cell death.","oneSentence":"Epidoxorubicine is an anthracycline antibiotic that intercalates DNA strands, thereby inhibiting the progression of topoisomerase II and inducing apoptosis in cancer cells. Docetaxel is a taxane that stabilizes microtubules, preventing cell division and leading to cell death. Cyclophosphamide is an alkylating agent that adds an alkyl group to DNA, causing cross-linking and DNA damage, which ultimately leads to cell death.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:11:04.127Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic breast cancer"},{"name":"Metastatic non-small cell lung cancer"},{"name":"Metastatic ovarian cancer"}]},"trialDetails":[{"nctId":"NCT00174707","phase":"PHASE3","title":"Study of Docetaxel in Breast Cancer Patients","status":"COMPLETED","sponsor":"Sanofi","startDate":"1997-12","conditions":"Breast Neoplasms","enrollment":998}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"epidoxorubicine, docetaxel, cyclophosphamide","genericName":"epidoxorubicine, docetaxel, cyclophosphamide","companyName":"Sanofi","companyId":"sanofi","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Epidoxorubicine is an anthracycline antibiotic that intercalates DNA strands, thereby inhibiting the progression of topoisomerase II and inducing apoptosis in cancer cells. Docetaxel is a taxane that stabilizes microtubules, preventing cell division and leading to cell death. Cyclophosphamide is an alkylating agent that adds an alkyl group to DNA, causing cross-linking and DNA damage, which ultimately leads to cell death. Used for Metastatic breast cancer, Metastatic non-small cell lung cancer, Metastatic ovarian cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}